vs
Electromed, Inc.（ELMD）とTransMedics Group, Inc.（TMDX）の財務データ比較。上の社名をクリックして会社を切り替えられます
TransMedics Group, Inc.の直近四半期売上が大きい（$160.8M vs $18.9M、Electromed, Inc.の約8.5倍）。TransMedics Group, Inc.の純利益率が高く（65.6% vs 14.6%、差は50.9%）。TransMedics Group, Inc.の前年同期比売上増加率が高い（32.2% vs 16.3%）。TransMedics Group, Inc.の直近四半期フリーキャッシュフローが多い（$19.0M vs $2.4M）。過去8四半期でTransMedics Group, Inc.の売上複合成長率が高い（28.8% vs 16.7%）
エレクトロメッド社は呼吸器ケア機器の開発・製造・販売を事業とする医療機器企業で、主力製品は高頻度胸壁振動を利用した痰排出システムです。主に米国の在宅ケア事業者や医療機関向けに製品を供給し、嚢胞性線維症やCOPDなどの呼吸器疾患患者の気道ケアを支援しています。
TransMedics Group, Inc.は臓器移植向けの革新的な医療技術を開発・販売する企業です。主力製品の臓器ケアシステムは輸送中のドナー臓器の生存性を維持し、心臓、肺、肝臓、腎臓移植の成功率向上に貢献し、北米、欧州、アジア太平洋地域の移植センターなどにサービスを提供しています。
ELMD vs TMDX — 直接比較
損益計算書 — Q2 2026 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $18.9M | $160.8M |
| 純利益 | $2.8M | $105.4M |
| 粗利率 | 78.4% | 58.1% |
| 営業利益率 | 19.2% | 13.2% |
| 純利益率 | 14.6% | 65.6% |
| 売上前年比 | 16.3% | 32.2% |
| 純利益前年比 | 40.3% | 1436.9% |
| EPS（希薄化後） | $0.32 | $2.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $18.9M | $160.8M | ||
| Q3 25 | $16.9M | $143.8M | ||
| Q2 25 | $17.4M | $157.4M | ||
| Q1 25 | $15.7M | $143.5M | ||
| Q4 24 | $16.3M | $121.6M | ||
| Q3 24 | $14.7M | $108.8M | ||
| Q2 24 | $14.8M | $114.3M | ||
| Q1 24 | $13.9M | $96.8M |
| Q4 25 | $2.8M | $105.4M | ||
| Q3 25 | $2.1M | $24.3M | ||
| Q2 25 | $2.2M | $34.9M | ||
| Q1 25 | $1.9M | $25.7M | ||
| Q4 24 | $2.0M | $6.9M | ||
| Q3 24 | $1.5M | $4.2M | ||
| Q2 24 | $1.8M | $12.2M | ||
| Q1 24 | $1.5M | $12.2M |
| Q4 25 | 78.4% | 58.1% | ||
| Q3 25 | 78.1% | 58.8% | ||
| Q2 25 | 78.3% | 61.4% | ||
| Q1 25 | 78.0% | 61.5% | ||
| Q4 24 | 77.7% | 59.2% | ||
| Q3 24 | 78.3% | 55.9% | ||
| Q2 24 | 76.2% | 60.6% | ||
| Q1 24 | 74.8% | 61.9% |
| Q4 25 | 19.2% | 13.2% | ||
| Q3 25 | 15.8% | 16.2% | ||
| Q2 25 | 17.5% | 23.2% | ||
| Q1 25 | 13.6% | 19.1% | ||
| Q4 24 | 15.6% | 7.1% | ||
| Q3 24 | 13.2% | 3.6% | ||
| Q2 24 | 15.7% | 10.9% | ||
| Q1 24 | 13.3% | 12.8% |
| Q4 25 | 14.6% | 65.6% | ||
| Q3 25 | 12.6% | 16.9% | ||
| Q2 25 | 12.7% | 22.2% | ||
| Q1 25 | 12.1% | 17.9% | ||
| Q4 24 | 12.1% | 5.6% | ||
| Q3 24 | 10.0% | 3.9% | ||
| Q2 24 | 12.3% | 10.7% | ||
| Q1 24 | 10.8% | 12.6% |
| Q4 25 | $0.32 | $2.59 | ||
| Q3 25 | $0.25 | $0.66 | ||
| Q2 25 | $0.26 | $0.92 | ||
| Q1 25 | $0.21 | $0.70 | ||
| Q4 24 | $0.22 | $0.19 | ||
| Q3 24 | $0.16 | $0.12 | ||
| Q2 24 | $0.20 | $0.35 | ||
| Q1 24 | $0.17 | $0.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $13.8M | — |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $45.4M | $473.1M |
| 総資産 | $54.9M | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $13.8M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $15.3M | — | ||
| Q1 25 | $15.2M | — | ||
| Q4 24 | $16.2M | — | ||
| Q3 24 | $13.9M | $330.1M | ||
| Q2 24 | $16.1M | $362.8M | ||
| Q1 24 | $11.7M | $350.2M |
| Q4 25 | $45.4M | $473.1M | ||
| Q3 25 | $44.7M | $355.2M | ||
| Q2 25 | $43.2M | $318.1M | ||
| Q1 25 | $43.9M | $266.3M | ||
| Q4 24 | $43.6M | $228.6M | ||
| Q3 24 | $41.5M | $209.9M | ||
| Q2 24 | $44.5M | $189.9M | ||
| Q1 24 | $42.5M | $159.5M |
| Q4 25 | $54.9M | $1.1B | ||
| Q3 25 | $53.6M | $946.0M | ||
| Q2 25 | $53.8M | $890.5M | ||
| Q1 25 | $52.5M | $837.5M | ||
| Q4 24 | $52.3M | $804.1M | ||
| Q3 24 | $48.9M | $785.6M | ||
| Q2 24 | $52.2M | $758.6M | ||
| Q1 24 | $48.9M | $723.8M |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $3.0M | $34.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $2.4M | $19.0M |
| FCFマージンFCF / 売上 | 12.7% | 11.8% |
| 設備投資強度設備投資 / 売上 | 3.4% | 9.7% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 0.33× |
| 直近12ヶ月FCF直近4四半期 | $7.9M | $133.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $3.0M | $34.5M | ||
| Q3 25 | $169.0K | $69.6M | ||
| Q2 25 | $3.9M | $91.6M | ||
| Q1 25 | $2.1M | $-2.9M | ||
| Q4 24 | $3.2M | $19.7M | ||
| Q3 24 | $2.3M | $6.9M | ||
| Q2 24 | $4.5M | $25.7M | ||
| Q1 24 | $1.4M | $-3.4M |
| Q4 25 | $2.4M | $19.0M | ||
| Q3 25 | $-83.0K | $61.9M | ||
| Q2 25 | $3.7M | $82.5M | ||
| Q1 25 | $1.9M | $-29.9M | ||
| Q4 24 | $2.9M | $6.1M | ||
| Q3 24 | $2.3M | $-41.3M | ||
| Q2 24 | $4.5M | $2.0M | ||
| Q1 24 | $1.3M | $-47.6M |
| Q4 25 | 12.7% | 11.8% | ||
| Q3 25 | -0.5% | 43.1% | ||
| Q2 25 | 21.4% | 52.4% | ||
| Q1 25 | 12.2% | -20.8% | ||
| Q4 24 | 18.0% | 5.0% | ||
| Q3 24 | 15.5% | -38.0% | ||
| Q2 24 | 30.1% | 1.7% | ||
| Q1 24 | 9.1% | -49.2% |
| Q4 25 | 3.4% | 9.7% | ||
| Q3 25 | 1.5% | 5.3% | ||
| Q2 25 | 0.8% | 5.8% | ||
| Q1 25 | 1.0% | 18.8% | ||
| Q4 24 | 1.4% | 11.2% | ||
| Q3 24 | 0.3% | 44.3% | ||
| Q2 24 | 0.1% | 20.8% | ||
| Q1 24 | 0.6% | 45.6% |
| Q4 25 | 1.10× | 0.33× | ||
| Q3 25 | 0.08× | 2.86× | ||
| Q2 25 | 1.75× | 2.62× | ||
| Q1 25 | 1.10× | -0.11× | ||
| Q4 24 | 1.60× | 2.87× | ||
| Q3 24 | 1.57× | 1.63× | ||
| Q2 24 | 2.46× | 2.11× | ||
| Q1 24 | 0.90× | -0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ELMD
セグメントデータなし
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
